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Background
In Italy, about 600,000 patients are affected by ulcers of
neuro-vascular origin, 50% of which are represented by
venous chronic ulcers, inveterate and painful. (Surveying
of the Ministry of Health – 2001). Of these approximately
60% are constituted by elderly patients.
Objective
To verify the results obtained in 240 elderly patients, age
ranged between 70 and 92 years-old (66.9% females –
31.1% males), affected with ulcers of the lower limbs,
treated by cultivated autografts of skin, from April 2001 to
August 2008.
Materials and methods
The biotechnologies are based on the drawing of a small
fragment of skin (2–3 cmq), at the elbow. Subsequently,
the skin fragment is sent to a specialized laboratory in cel-
lular cultivated membrane, where it is divided into its two
essential components: dermatocytes and cheratinocytes.
These, after having been separated, centrifugated and
implanted on an adapted medium which consists of mod-
ified three-dimensional jaluronic acid, develop in vitro an
extended layer of tissue (dimensions 100–200 cmq),
which then will be grafted separately (after 4 weeks from
the biopsy) on the surface of the ulcer.
For the correct execution of such procedure are necessary
four surgical steps, in sequence:
1. The debridement of the ulcer, the elasto-compressive
bendage of the leg and the drawing of the skin.
2. The grafting of the layer of dermatocytes (called Hyalo-
graft 3D) after 22–30 days.
3. The grafting of the layer of cheratinocytes (called Laser-
skin), after others 22–30 days.
4. The surgical treatment of the venous or arterial insuffi-
ciency after 1–10 months.
Results
We have performed a total of 520 autografts (234 derma-
tocytes – 286 cheratinocytes). Approximately half of the
ulcers treated, were venous chronic ulcers, inveterate and
painful secondary to chronic venous insufficiency of the
lower limbs and/or post-thrombotic syndrome.
A clinical follow-up was performed on 186 out of the 240
cases, medially for 26 months (ranging between 3 months
– 7 years and 4 months). In reference our experience, on
the 240 cases treated, we have obtained 207 cases
(86.25%) of complete healing, 27 cases (11.25%) of par-
tial healing, with a reduction of the ulcerated area >50%,
6 cases (2.5%) of therapeutic failure, with a reduction of
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the ulcerated area <50%, 2 cases (0.83%) of amputations
and 18 cases (7.5%) of relapses. The mean time for the
complete closing of the ulcers has been of 13.4 weeks cal-
culated by the date of the first graft (range 4.1–33.2
weeks). Data on line to the more recent literature, in
which is described a percentage of 95% of good clinical
results (ulcers partially and completely closed) and stable
in the time.
Conclusion
The advantages of this surgical method, by now univer-
sally accepted, are, therefore, of remarkable clinical and
social relief and we can summarize them as follows:
1. The proved clinical effectiveness;
2. The security of the biotechnological procedure in terms
of microbiological pollution of the samples;
3. The long-lasting results;
4. A positive relationship between cost and benefits.
In addition, we completely agree in asserting that such a
procedure is easy and fast in execution, well-tolerated and
able to replace the traditional and very more complex sur-
gical methods.Page 2 of 2
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